Status:
COMPLETED
Ketorolac vs. Steroid in the Prevention of CME
Lead Sponsor:
Innovative Medical
Conditions:
Cataract
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Evaluate if the incidence of sub clinical CME can be significantly reduced by use of peri-operative Acular LS plus Pred Forte when compared with Pred Forte alone in normal cataract patients.
Eligibility Criteria
Inclusion
- · Male or female \> 18 years of age scheduled to undergo cataract surgery with surgeon expectation of 20/20 BCVA postoperatively
- Must be in good general health. Patients with systemic diseases will be enrolled only if there are no ocular manifestations of their disease (ie diabetics with normal retinal exams)
- Ability to provide informed consent and likely to complete all study visits
Exclusion
- · Known contraindication to any study medication or any of their components
- Uncontrolled systemic disease
- Required use of ocular medications other than the study medications during the study
- Abnormal pre-operative OCTs if obtainable
- Diabetic patients with a history of macular edema or diabetic retinopathy
- AMD patients with less than a 20/20 surgical outcome expectation, epi-retinal membranes, retinal vein occlusion, or any pre-existing macular disease
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00348244
Last Update
January 17 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr. Wittpenn
Stony Brook, New York, United States, 11790